太龍藥業(600222.SH)放棄子公司增資優先認繳出資權 擬為新領先引入新投資者
格隆匯5月26日丨太龍藥業(600222.SH)公佈,基於對新領先投資價值及未來發展的認可、支持深藍海的遷址落户及經營發展,京港基金擬與公司簽訂《增資協議》,對深藍海、新領先增資,最終取得新領先12.62%股權。本次增資具體安排如下:
深藍海遷址至產業園,並更名為鄭州深藍海生物醫藥科技有限公司(最終以工商登記為準)。
京港基金以現金方式向深藍海增資人民幣1.3億元,其中增加註冊資本550萬元,增加資本公積1.245億元。新領先作為原股東放棄本次增資優先認繳出資權。
京港基金以其持有的深藍海20%股權向新領先增資人民幣1.3億元,其中增加註冊資本1155.42萬元,增加資本公積1.18億元。公司作為原股東放棄本次增資優先認繳出資權。
公司本次增資擴股引入投資者能夠為新領先補充流動資金,優化股本結構,推動新領先現有業務規模和效益的全面提升;同時增資完成後,新領先、深藍海還將使用部分增資款直接投資並參與運營產業園已建成的CDMO等技術平台,實現產業升級,形成CRO至CDMO的全產業鏈佈局,提升公司的行業地位和市場競爭能力,符合公司發展戰略。本次交易完成後,新領先、深藍海仍為公司控股子公司,納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.